First identified as a potential cognitive enhancer in 1996 by Terranova and colleagues at the French pharmaceutical development firm, Sanofi, Rimonabant was found to be of interest due to its ability to reverse the inhibition of hippocampal synaptic plasticity caused by the CBR1 agonist, WIN 55,212-2
Clients can return to their daily activities immediately following treatment, with no required downtime
In the intrinsic pathway, oxidative stress or GSH depletion induces BAX SSG at Cys62, promoting its mitochondrial translocation and subsequent activation of CASP9 and CASP3 44
In addition, glycine and glutamate deficiency also affects GSH synthesis to some extent [23]
Its primary mechanism involves upregulating actin, a protein fundamental to cell structure, movement, and regeneration
L., Barton Duell, P